Literature DB >> 32376146

Skin cancer plastic surgery during the COVID-19 pandemic.

Stefano Gentileschi1, Anna Amelia Caretto2, Luca Tagliaferri3, Marzia Salgarello4, Ketty Peris5.   

Abstract

Entities:  

Keywords:  COVID-19; SARS-COV-2; Skin cancer; Skin malignancies

Mesh:

Year:  2020        PMID: 32376146      PMCID: PMC7252046          DOI: 10.1016/j.ejso.2020.04.048

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


× No keyword cloud information.
Dear editor Since the first cases occurring in Wuhan, China, in December 2019, the Coronavirus disease 2019 (COVID-19) quickly spread worldwide, being declared as pandemic by OMS. The number of infected people has rapidly increased, and on April 19th, 2020, it was estimated that it was present in 184 different countries accounting for more than 2,4million confirmed cases. This scenario has created a dramatic burden over the healthcare systems that have been forced to set up new intensive care units and to create, within the existing hospitals, dedicated COVID-Hospitals, with separated clinical pathways for infected and non-infected patients. Such an emergency situation significantly reduced elective surgery, to limit as much as possible the risks of SARS-CoV-2 virus infection for both patients and medical and healthcare personnel and to leave the clinical facilities and intensive care available for a possible huge access of COVID patients. Skin malignancies’ priorities can be difficult to evaluate for plastic surgeon because skin cancer can range from very slowly progressing types that can be deferred, to aggressive forms. Our Hospital is one of the most important cancer centres in Italy and, at the same time, one of the most important COVID-Hospital established for the pandemic. Then, a variety of clinical scenarios have been assessed by our group since the pandemic began. Although a careful selection of patients who are candidate for treatment by plastic surgeons is mandatory, there are no suggestions in the literature on which precise criteria the priority list should be based. Until now, the risk of a significant worsening of the disease prognosis within 30 days has been the most important parameter for our priority list. According to the cases treated using this principle, we believe that the following situations should be considered for surgery: 1) Patients with a recent excision of melanoma, who need to undergo re-excision and sentinel node biopsy (SNB). In case of positive SNB, these patients can access to specific adjuvant therapies, to be started as soon as possible to limit the risk of systemic relapse [1]; 2) Bleeding ulcerated skin cancer. Some skin malignancies may cause recurring episodes of bleeding and discharge requiring emergency room access, exposing the patient to complications and possibility to be infected with SARS-CoV-2 for the repeated entrance in the first aid; 3)Oncologic patients who are followed-up for solid tumours (gynecological/breast cancer, melanoma, etc.) and develop solitary and resectable cutaneous/subcutaneous metastasis. In such cases, wide resection of metastases may improve patient overall survival; 4) Occurrence of rapidly growing and aggressive skin cancers (melanoma, angiosarcoma,etc.). Wide excision of these malignancies should be performed as early as possible; 5) Surgery should be also carefully evaluated for rapidly growing basal cell or squamous cell carcinoma. In rare cases, or in fragile patients such as transplant patients, the tumoral growth rate can be fast and, according to the anatomical sites, they can also invade surrounding and deep structures requiring major reconstructive procedures or causing functional permanent impairment [2]. Lid cancer can be included in this group and could be considered a medium priority surgery to be delayed only for a short period of time. When managing patients undergoing surgery, some principles must be followed. Prior to admission to the Hospital/Department, screening for SARS-CoV-2 infection should be performed, by a nurse-directed triage, to exclude respiratory symptoms or recent contacts with affected people. The morning before surgery, each patient should undergo RT-PCR test on nasopharyngeal swabs. Then, the patient should be immediately hospitalized, to avoid the infection with SARS-CoV-2 after having undergone the test. During the same day the test results should be available and, if negative, the patient directed in a not-COVID clinical pathway and operating room(OR).In case of positive swab, surgical indication should be postponed [3], and with the use of telemedicine, the patient should be follow-up for worsening of the disease during home quarantine and re-evaluated with swab after confirmed infection clearance. In case of an emergency situation such as bleeding the surgical procedures cannot be deferred and a dedicated in-patient unit, clinical pathway and OR should be available for SARS-CoV-2 surgical patients. Specific counselling about the increased risks of undergoing surgery during the COVID-19 incubation period should be done [4].

Declaration of competing interest

None.
  4 in total

1.  Short-course radiotherapy in elderly patients with early stage non-melanoma skin cancer: a phase II study.

Authors:  Marica Ferro; Francesco Deodato; Gabriella Macchia; Stefano Gentileschi; Savino Cilla; Gabriella Torre; Gilbert D A Padula; Marianna Nuzzo; Mariangela Massaccesi; Vincenzo Valentini; Alessio G Morganti
Journal:  Cancer Invest       Date:  2015-03       Impact factor: 2.176

2.  Was the surgeon a satisfactory informant? How to minimize room for claims.

Authors:  Roberto Bracaglia; Marco D'Ettorre; Stefano Gentileschi; Damiano Tambasco
Journal:  Aesthet Surg J       Date:  2014-05-01       Impact factor: 4.283

3.  Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers.

Authors:  Concetta Santonocito; Paola Concolino; Maria Michela Lavieri; Franco Ameglio; Stefano Gentileschi; Rodolfo Capizzi; Sandro Rocchetti; Pierluigi Amerio; Massimo Castagnola; Cecilia Zuppi; Ettore Capoluongo
Journal:  Clin Chim Acta       Date:  2005-07-27       Impact factor: 3.786

4.  Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.

Authors:  Shaoqing Lei; Fang Jiang; Wating Su; Chang Chen; Jingli Chen; Wei Mei; Li-Ying Zhan; Yifan Jia; Liangqing Zhang; Danyong Liu; Zhong-Yuan Xia; Zhengyuan Xia
Journal:  EClinicalMedicine       Date:  2020-04-05
  4 in total
  6 in total

1.  Effects of the COVID-19 pandemic on care of melanoma patients in Berlin, Germany: the Mela-COVID survey

Authors:  Miriam Teuscher; Katharina Diehl; Marthe-Lisa Schaarschmidt; Juliane Weilandt; Bianca Sasama; Jan Ohletz; Andreas Könnecke; Wolfgang Harth; Uwe Hillen; Wiebke Katharina Peitsch
Journal:  Eur J Dermatol       Date:  2021-08-26       Impact factor: 2.805

2.  Lymphatic Function of the Lower Limb after Groin Dissection for Vulvar Cancer and Reconstruction with Lymphatic SCIP Flap.

Authors:  Anna Amelia Caretto; Gianluigi Stefanizzi; Simona Maria Fragomeni; Alex Federico; Luca Tagliaferri; Valentina Lancellotta; Giovanni Scambia; Stefano Gentileschi
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

3.  COVID-19 and cancer: Looking for evidence.

Authors:  Diego Serraino
Journal:  Eur J Surg Oncol       Date:  2020-05-06       Impact factor: 4.424

4.  COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy.

Authors:  Cesar Martins da Costa; Zenaide Silva de Souza; Alessandra Corte Real Salgues; Guilherme Harada; Pedro Paulo Marino Rodrigues Ayres; Daniela Bulhões Vieira Nunes; Artur Katz; Rodrigo Ramella Munhoz
Journal:  Immunotherapy       Date:  2020-09-09       Impact factor: 4.196

Review 5.  The COVID-19 pandemic and its impact on esthetic dermatology.

Authors:  Zeinab Aryanian; Amirhooshang Ehsani; Zahra Razavi; Shahin Hamzelou; Zeinab Mohseni Afshar; Parvaneh Hatami
Journal:  J Cosmet Dermatol       Date:  2022-09-15       Impact factor: 2.189

6.  The Impact of and Adaptations Due to the COVID-19 Pandemic on the Histopathological Diagnosis of Skin Pathologies, Including Non-Melanocyte and Melanoma Skin Cancers-A Single-Center Study in Romania.

Authors:  Iuliu-Gabriel Cocuz; Maria-Elena Cocuz; Raluca Niculescu; Mihaela Cornelia Șincu; Andreea Cătălina Tinca; Adrian-Horațiu Sabău; Diana Maria Chiorean; Silviu Horia Morariu; Ovidiu Simion Cotoi
Journal:  Medicina (Kaunas)       Date:  2021-05-27       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.